Valencia Town Center Pharmacy
Community pharmacy in Valencia, California

Flibanserin (Addyi) 100 mg: U.S. Product and Access Guide

Addyi is the U.S. brand name for flibanserin, a prescription tablet with a current FDA-approved indication that is narrower than general “female libido” marketing sometimes found online. The current U.S. prescribing information states that Addyi is indicated for women younger than 65 years with acquired, generalized hypoactive sexual desire disorder (HSDD) when the low sexual desire causes marked distress or interpersonal difficulty and is not due to another medical or psychiatric condition, relationship problems, or the effects of a medication or other drug substance. The label also states that Addyi is not indicated in men and is not intended to enhance sexual performance.

Addyi and flibanserin are not interchangeable terms for every product

Flibanserin is the active ingredient. Addyi is the FDA-approved branded drug product. Current DailyMed labeling identifies Sprout Pharmaceuticals, Inc. as the packager and lists Addyi as a 100 mg film-coated tablet under NDA 022526. The current product is prescription only.

A generic name is not the same thing as an FDA-approved generic drug product. A current DailyMed search for flibanserin identifies the Addyi product; it does not show a separately marketed ANDA generic flibanserin product. For product research, the safest approach is therefore to refer to flibanserin as the active ingredient and Addyi as the currently identified FDA-approved U.S. product rather than implying that a generic equivalent is available.

Current FDA indication

The indication changed in late 2025. Earlier materials may describe Addyi as a treatment only for premenopausal women. The current FDA-approved labeling, revised in December 2025, extends the indication to women younger than 65 years regardless of reproductive status, while retaining the requirement that HSDD be acquired and generalized and not explained by another condition, relationship issue, medication, or drug substance.

This is a useful example of why current labeling matters more than old pharmacy copy, old articles, or an old search result. Anyone comparing product information should check the date of the source rather than relying on a historical description of the indication.

Strength, dosage form and prescription status

Addyi is supplied as a 100 mg oral tablet. The FDA-approved labeling describes a once-daily bedtime regimen, while individual treatment decisions belong with the prescriber and dispensing pharmacist. The prescribed dose, contraindications, interacting medicines, alcohol precautions and whether treatment remains appropriate require patient-specific review.

The product carries a boxed warning concerning hypotension and syncope in certain settings. The label specifically addresses alcohol timing, moderate or strong CYP3A4 inhibitors and hepatic impairment. These restrictions are part of the product identity and are important when comparing Addyi with unverified online products that may omit U.S. labeling or safety information.

What to verify before obtaining flibanserin

A prescription product should be verified by more than the active-ingredient name. Useful questions include whether the prescription is for Addyi 100 mg, whether the pharmacy can identify the manufacturer or labeler and NDC of the product it would dispense, whether current insurance or formulary rules apply, and whether prior authorization or another coverage step is required. Cash price and insurance cost can differ, so a quoted price should be tied to a specific pharmacy, product and date rather than treated as a permanent national price.

Patients should also make sure the product supplied matches an FDA-listed U.S. drug product rather than a foreign-market or unverified “generic Addyi” listing. Packaging, tablet appearance and seller claims alone are not enough to establish FDA approval.

Approval status versus a “generic name” search

The regulatory pathway is also useful when checking product identity. DailyMed lists Addyi under a New Drug Application (NDA), not an Abbreviated New Drug Application (ANDA). In ordinary U.S. drug research, an ANDA is the pathway used for an approved generic version of a reference listed drug. The current flibanserin search result available through DailyMed shows the Addyi NDA product rather than a separate ANDA-labeled flibanserin tablet. Accordingly, the available records do not support describing flibanserin as a currently marketed generic Addyi product simply because flibanserin is the drug’s nonproprietary name.

The distinction can affect both expectations and cost. A patient may find websites that use “generic Addyi” as a keyword, but the relevant question is whether the offered product corresponds to an FDA-approved U.S. drug application and current label. If a product cannot be matched to a U.S. label, NDC, responsible labeler and approval pathway, its regulatory identity remains unclear.

What changed in 2025

The December 2025 labeling update is particularly important when comparing older sources. Earlier FDA materials and older Addyi labeling described use in premenopausal women. The current label now includes women younger than 65 years and contains clinical-study sections for both premenopausal and postmenopausal patients under 65. A source dated before the change may still be accurate historically while being incomplete for current product research.

Asking Valencia Town Center Pharmacy about Addyi

Contact the pharmacy to confirm current availability, product identity and coverage for a specific prescription.

For broader patient-facing information, see Medication & Pharmacy Resources.